The report “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics, For more mail: vikas@konceptanalytics.com

1. Global Thalassemia Market:
Industry Analysis & Outlook
-----------------------------------------
(2017-2021)
Industry Research by Koncept Analytics
1
December 2017
Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)

2. Executive Summary
2Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a
genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two
proteins called alpha globin and beta globin. A person inherits four genes to produce alpha globin protein and
two genes to produce alpha globin protein from parents. Thalassemia is caused by any abnormality or mutation
in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene
from parents then the person becomes a carrier of thalassemia. Since, thalassemia is an inherited disorder; one
of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving
birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and
beta thalassemia.
Globally, thalassemia affects approximately 7% of the population and many of them are transfusion dependent
patients. The global thalassemia market is likely to be driven with the growing market of bone marrow
transplant and blood transfusion therapy, supported by high numbers of transfusion dependent patients.
The U.S. is expected to be the first region to start selling of thalassemia drugs due to developing drug pipeline
and later on, market penetration of thalassemia drugs would occur in Europe. U.S. and Europe have high
prevalence of severe forms of beta-thalassemia which would result into a high demand for thalassemia drugs in
future.
The global thalassemia market is expected to grow in future with mounting prevalence of thalassemia, rising
Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell
therapy research. Key trends of this market include progressing drug pipeline, rising scope for gene therapy
and growing awareness towards thalassemia. However, there are some factors which can hinder growth of the
market including regulatory changes, associated risks and high cost of treatment.
The report “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics
provides an extensive research and detailed analysis of the present market along with future outlook. The
report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with
the global market. The report profiles key players of the market including GlaxoSmithKline Plc, Celgene,
Bluebird Bio and Bellicum Pharmaceuticals.

3. Global thalassemia market is likely to witness growth due to rising global population of
thalassemia, increasing development of drug therapies and gene therapies…
3
Global Thalassemia Market: Industry Analysis & Outlook
(2017-2021)
• In 2016, population of non-severe patients held a
share of ..% in the global thalassemia population
whereas severe population held a share of ..%.
• In 2021, global bone marrow market is predicted to be
valued at US$.. billion increasing from US$.. billion in
2016, growing at a CAGR of % for the period spanning
2016-2021.
• In year 2025, global Luspatercept revenue for beta-
thalassemia is expected to reach US$.. million,
increasing from US$.. million in 2019, at a CAGR of
..%.
Global Bone Marrow Market Forecast by Value (2016-
2021)
Global Thalassemia Population by Category (2016)
Global Luspatercept Revenue Forecast for Beta-Thalassemia (2019-
2025)

4. Thalassemia market of the U.S. and Europe are expected to rise in future due to rising population
of beta-thalassemia supported by growing number of immigrants from Asian and African
countries…
4
Global Thalassemia Market: Industry Analysis & Outlook
(2017-2021)
• The U.S. beta-thalassemia patient volume is expected
to reach … in the year 2021, increasing from … in the
year 2016 at a CAGR of ..%.
• In the year 2021, European beta-thalassemia
population is expected to reach ..thousand, increasing
from …thousand in 2016, growing at a CAGR of %.
• In year 2025, European Luspatercept drug revenue is
predicted to be valued at US$.. million, increasing from
US$.. million in 2020, at a CAGR of ..%.
Europe Beta-Thalassemia Patient Volume Forecast (2016-2021)
The U.S. Beta-Thalassemia Patient Volume Forecast (2016-2021)
Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2020-
2025)

5. Koncept Analytics
CS-36, First Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T: +91-120-4130959
M: +91-9871694789
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
This is a licensed product of Koncept Analytics. You cannot reproduce, publish, distribute, publicly display, sell or create
other works from this report or use them in any way for commercial purpose without our prior permission. Further, you
cannot copy this material, by any means (including electronic copies), for distribution to others unless you have purchased
the corporate license of this report.
We believe the sources are reliable, but Koncept Analytics does not warranty the accuracy or completeness of the data. The
data presented in the report is updated at the publication date but is subject to change at subsequent releases. All possible
efforts have been made to ensure accuracy of data. However, investors should not completely rely on the information given
in this report and must make decisions based on their own investment strategy, risk management and capital adequacy.
For Report Purchase Click Below:
http://www.konceptanalytics.com/Researchreport/global-thalassemia-market-industry-analysis-outlook-
2017-2021-31472.aspx
Disclaimer